Agenus reports three-year ovarian cancer survival data for botensilimab combination
Agenus presented three-year follow-up from the ovarian cancer group in its Phase 1b C-800-01 study at the 2026 IGCS Annual Global Meeting. Estimated overall survival at three years was 48% among 35 efficacy-evaluable patients receiving botensilimab with balstilimab, matching the two-year estimate. At the latest assessment, 25% of the 44 patients dosed were alive without ongoing therapy.
Why it matters
The update supplies longer-term data for Agenus' unapproved botensilimab and balstilimab regimen in recurrent ovarian cancer. Agenus said the results reinforce its belief that the combination could provide durable benefit for a subset of heavily treated patients.
Key facts
- 1The ovarian cohort was part of Agenus' Phase 1b C-800-01 trial, which enrolled 400+ patients across cancers. recorder.ca
- 2Estimated overall survival was 48% at both two years and three years in the 35 patients assessed for efficacy. recorder.ca
- 3Median overall survival was 14.8 months. recorder.ca
- 4Eleven of 44 treated patients, or 25%, were alive and not receiving therapy at the last follow-up. recorder.ca
- 5Participants had previously undergone a median of four treatment regimens, and 66% had undergone four or more. recorder.ca
- 6Agenus said BOT and BAL remain in development and lack U.S. Food and Drug Administration approval. recorder.ca
Open questions
- The materials do not provide a control group or comparative efficacy data against another treatment.
- The reported survival outcomes are estimates from a Phase 1b cohort and the products are not approved.
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.